European Biotechnology

To begin with, European Biotechnology is your go-to platform for comprehensive insights into the life science sector across Europe.

International, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#2175597

United States

#1533788

Health/Biotechnology and Pharmaceuticals

#1442

Traffic sources

Monthly visitors

Articles

Big deal: Amphistar goes transatlantic

2 days ago | european-biotechnology.com | Thomas Gabrielczyk

Under a new strategic partnership, North American producer of high-purity surfactants Kensing Solutions LLC will exclusively market Leuven-based AmphiStar BV’s 100% microbially upcycled biosurfactants to the personal care market and HI&I Industries (Household, Industrial & Institutional). AmphiStar will use local agri-food side streams to produce its sustainable biosurfactants.
Pharma industry calls EU pharma package counterproductive

3 days ago | european-biotechnology.com | Thomas Gabrielczyk

The criticism from the EU pharmaceutical association EFPIA and the German VFA is directed primarily at the restriction of property rights for pharmaceutical innovations, in particular for orphan drugs, which currently enjoy 20 years of patent protection plus a five-year supplementary protection certificate (SPC) and up to 11 years of data exclusivity protection (8 + 2 + 1) after approval.
Super deal for BioNTech – BMS licenses potential blockbuster for €10bn - European Biotechnology Magazine

4 days ago | european-biotechnology.com | Thomas Gabrielczyk

The deal, announced just in time for the world’s largest cancer meeting, ASCO, shows the struggle among pharmaceutical giants to find a successor to MSD’s immuno-oncology blockbuster pembrolizumab, which generated sales of US$15bn in 2024. The first market approval in the US could go to the bispecific VEGFxPD1 antibody ivonescimab from Chinese company Akeso, licensed by Summit Therapeutics for US$500m upfront.
Scotland’s bioeconomy gets scale-up boost

5 days ago | european-biotechnology.com | Thomas Gabrielczyk

Located at FlexBIO, the Industrial Biotechnology Innovation Centre’s (IBioIC) scale-up facility at Heriot-Watt University in Edinburgh, installation of the new fermenter was made possible by a £847,000 grant from Scottish Enterprise, Scotland’s national economic development agency. The investment expands IBioIC’s scale-up capabilities significantly, increasing upstream bioprocessing capacity tenfold – from 30 litres to 300 litres.
Scientists uncover target to stop colitis-induced colorectal cancer

6 days ago | european-biotechnology.com | Thomas Gabrielczyk

Led by Ahmed Hegazy at Charité University Hospital in Berlin, the team was investigating cancer-promoting factors in patients with ulcerative colitis. They found that receptors for the inflammation-promoting cytokine Oncostatin M (OSM) were frequently present in tumours. In intestinal cells, the team observed that the cytokine IL-22 induced the activation of the OSM-beta receptor by increasing both STAT3 expression and the expression of the receptor itself.
EU set to improve investment for biotech start-ups and scale-ups

1 week ago | european-biotechnology.com | Thomas Gabrielczyk

The European Commission has unveiled a new strategy entitled ‘Choose Europe to start and scale’, which aims to strengthen the development and financing of start-ups and scale-ups within the European Union, particularly in innovation-driven sectors such as biotechnology, quantum computing and deep tech. The strategy, published on 28 May 2025, addresses the challenges faced by start-ups and growth companies in scaling up their production in the EU.
Norwegian Mycelium AS bags €1.25m to scale mycoprotein production

1 week ago | european-biotechnology.com | Thomas Gabrielczyk

The strategic partnership of Norwegian Mycelium A/S with Nitten, first established in April 2024, aims to repurpose sidestreams from sugar beet processing into high-value protein using Norwegian Mycelium’s biomass fermentation platform. With the fresh capital, the 2020 start-up plans to expand its production capabilities and strengthen its position in the global alternative protein market.
Reproducible nanopore sequencing to be commercialised from 2026

1 week ago | european-biotechnology.com | Thomas Gabrielczyk

With the Broad Institute serving as a beta tester, Roche aims to first explore the potential applications of Sequencing by-Expansion (SBX)-Technology , which was introduced in February. The nanopore-based sequencing method will initially enter the global market in 2026 for Research Use Only (ROU). In the medium term, however, Roche intends to establish SBX as the gold standard for diagnostics and stratification in personalised medicine.
C4X Discovery bags milestone for IL-17A blocker from Sanofi

1 week ago | european-biotechnology.com | Thomas Gabrielczyk

Manchester university spin-out C4X Discovery Holdings Ltd has received a milestone payment of €8m from Sanofi SA reflecting progress in preclinical development of its ongoing oral IL-17A inhibitor programme. Under the terms of a licence deal dating back to April 2021, C4X Discovery is entitled to up to a total of €414m in upfront, pre-clinical, development, regulatory and commercialisation milestone payments plus single-digit royalties on future net sales.
New way to target mitochondrial diseases

1 week ago | european-biotechnology.com | Thomas Gabrielczyk

The market for mitochondrial diseases is currently small at just over €23m. However, it is growing by 28.5% annually until 2030 as the disease mechanisms of at least 1.6 million patients worldwide are increasingly being decoded. German scientists have now developed a method to silence specific mitochondria-encoded mRNAs in living cells, opening the avenue towards phenotypic screens.